Research programme: targeted nanoparticle tolerance therapeutics - AnTolRx

Drug Profile

Research programme: targeted nanoparticle tolerance therapeutics - AnTolRx

Alternative Names: TNTT

Latest Information Update: 16 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnTolRx
  • Class Antigens
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus
  • Research Autoimmune disorders

Most Recent Events

  • 14 Sep 2016 AnTolRx has patent protection for its therapies (AnTolRx website, September 2016)
  • 08 Sep 2016 Early research in Autoimmune disorders in USA
  • 08 Sep 2016 Preclinical trials in Type-1 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top